Subsequently, we performed Kaplan-Meier survival and log-rank test, observing that patients with hypermethylation level of CLDN11 harbored low progression free survival (PFS) (P = 0.041) (Figure 8), which indicated CLDN11 methylation could serve as a useful prognosis biomarker for CRC. This evidence concerns the gene CLDN11 and colorectal carcinoma.